AIM Vaccine’s 13-valent pneumonia conjugate vaccine obtained Production license
- Written by The Bulletin
Application for drug marketing registration duly submitted Super heavyweight items are expected to drive performance soaring
HONG KONG SAR - Media OutReach Newswire – 1 November 2024 - AIM Vaccine (06660.HK) announced on 1st November that the application for drug marketing registration of the Company's independently developed 13-valent pneumonia conjugate vaccine has been submitted to the National Medical Products Administration.Read more: AIM Vaccine’s 13-valent pneumonia conjugate vaccine obtained Production license
